HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a 'Buy' rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.
September 19, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Werewolf Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $15.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $15 indicates the firm's continued confidence in the stock's potential, which could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100